Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

editorial

. 2020 Apr;9(2):837–839. doi: 10.21037/tau.2020.03.24

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2020 Translational Andrology and Urology. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Progression of treatment-refractory castration-resistant PCa. The proposed mechanism and progression sequence suggested by Labrecque et al. in (9). The PCa cells after receiving ADT can progress to either ARPC, AMPC, SCNPC, or DNPC. ARPC can progress to ARLPC, DNPC, or QUAPC. ADT, androgen deprivation therapy; ABI, abiraterone; ENZ, enzalutamide; PC, hormone-sensitive prostate cancer; ARPC, AR-high prostate cancer; AMPC, amphicrine prostate cancer; SCNPC, small cell or NE prostate cancer; DNPC, double-negative prostate cancer; ARLPC, AR-low prostate cancer; SQUAPC, squamous prostate cancer.